Inhibiting Capillary Tube Regression via RIF Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of blood vessel formation is extensive, but the molecular basis for vessel regression is poorly understood, which limits therapeutic opportunities in diseases involving capillary loss or regression, such as ischemia, hypertension, and cancer, where capillary regression plays a key pathogenic role.
Innovation Solution
Administering a therapeutically effective amount of an inhibitor of capillary tube regression, specifically using pharmacologic agents like forskolin, IBMX, SB239, tubacin, or antibodies targeting IL-1β, TNFα, and thrombin to prevent capillary and lymphatic tube regression in patients with conditions like ischemia, hypertension, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the molecular basis for vessel regression is not understood, then therapeutic opportunities in diseases involving capillary loss are limited, but understanding vessel regression mechanisms requires extensive research investment and time
Solution Approach 1:
The patent performs preliminary identification and characterization of regression-inducing factors (RIFs) and their receptors before developing therapeutic interventions. By pre-mapping the molecular pathways involved in capillary regression through systematic screening and validation, the research establishes a foundation that accelerates future therapeutic development while reducing the time needed for clinical translation
2Object-affected harmful factors
If capillary regression mechanisms are not targeted, then diseases like ischemia and cancer progress unchecked, but developing specific inhibitors requires identifying precise molecular targets
Solution Approach 1:
The patent segments the complex capillary regression process into distinct molecular components: regression-inducing factors (RIFs), their specific receptors, and downstream signaling pathways. This segmentation allows for targeted intervention at specific points in the regression cascade, simplifying the development of selective inhibitors while effectively addressing capillary loss in diseases like ischemia and cancer
Solution Approach 2:
The patent identifies receptor proteins as intermediary targets that mediate the interaction between RIFs and endothelial cells. By targeting these intermediary receptors rather than the RIFs themselves or downstream effectors, the approach enables selective blockade of regression signaling while preserving other vascular functions, reducing the complexity of developing disease-specific therapies
3Object-generated harmful factors
If broad-spectrum anti-inflammatory agents are used, then multiple inflammatory pathways are suppressed, but this may cause unwanted side effects and lacks specificity
Solution Approach 1:
The patent applies the principle of local quality by developing inhibitors that specifically target RIF-receptor interactions in the vascular context rather than suppressing broad inflammatory pathways. This localized specificity ensures that anti-inflammatory effects are confined to the relevant vascular regression pathways, preventing unwanted side effects while effectively reducing inflammatory damage in diseases like atherosclerosis and arthritis
Data Source
AI summary
Compositions and methods of treatment for inhibiting capillary tube regression and/or lymphatic tube regression are described, as well as factors and signaling pathways that control the regression of capillary tube networks. Capillary tube regression and/or lymphatic tube regression may be implicated in ischemia, infarction, hypertension, diabetes, malignant cancer, neurodegenerative disease, wound repair response, atherosclerosis, pro-inflammatory disease, pro-thrombotic disease, viral infection (e.g., influenza or SARS-CoV-2), bacterial infection.